SCHEMBL7188997

SCHEMBL7188997

CCCOc1ccc(PC(=O)c2c(C)cc(C(C)(C)C)cc2C)c(OCCC)c1.[LiH]

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ACACB O00763 4/20 0.37
PPARG P37231 3/20 0.37
PPARD Q03181 3/20 0.37
PPARA Q07869 3/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
LMNA P02545 3/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SLC5A1 P13866 1/20 0.35
SLC5A2 P31639 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HTT P42858 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34
THRB P10828 1/20 0.34
NR1I2 O75469 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7189003 0.98 MAPT (0.38) MAPTSMN1; SMN2ACACBPPARGPPARD
SCHEMBL7183681 0.95 PPARG (0.39) MAPTPPARGPPARDPPARATHRB
SCHEMBL7179784 0.93 ITGB1 (0.39) PPARGPPARDPPARATHRB
Lithium SCHEMBL7183689 0.93 PPARG (0.37) MAPTPPARGPPARDPPARATHRB
SCHEMBL7182184 0.92 THRA (0.40) THRB
SCHEMBL7175802 0.91 MAPT (0.39) MAPTSMN1; SMN2ACACBPPARGPPARD
SCHEMBL7183117 0.90 MAPT (0.37) MAPTSMN1; SMN2ACACBPPARGPPARD
SCHEMBL7185499 0.90 CACNA1H (0.35) PPARGPPARDPPARAKMT2AL3MBTL1
SCHEMBL7182484 0.90 ITGB1 (0.40) MAPTSMN1; SMN2LMNAKMT2AL3MBTL1
SCHEMBL7178013 0.88 KDM4E (0.42) MAPTSMN1; SMN2CYP1A1CYP1B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885SMN1; SMN2 2939/4885ACACB 914/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885SMN1; SMN2 3105/4885ACACB 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.